Global pharmaceutical major Lupin is set to present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled in Berlin from October 17 to 21, 2025.
The presentation, titled “A Phase 1 Dose Escalation Study of LNP3693 (STING agonist) in Patients with Advanced or Metastatic Solid Tumors & Lymphoma”, will be featured under the Investigational Immunotherapy category (Presentation Number 1553P) and will be viewable on October 19, 2025, from 09:00 to 17:00 CEST.
LNP3693 is an investigational parenteral STING agonist designed to activate innate immune pathways for anti-tumor effects. The study presentation will share qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with advanced cancers.
“This marks another important milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, it is a privilege to present the findings of another Phase 1 clinical trial for LNP3693, a STING agonist, at ESMO. ESMO’s acknowledgment of the clinical research conducted in India underscores the proficiency of our team in oncology drug discovery, research, and clinical development,” said Vinita Gupta, CEO, Lupin.
The Phase 1 trial is registered under CTRI/2023/10/059147, and complete data will be shared during the official ESMO session.
All accepted abstracts, including Lupin’s, will be published online via the ESMO website on October 13, 2025, and featured in the ESMO Congress 2025 Abstract Book, a supplement to the Annals of Oncology. |
